VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
DSGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
DSGNDesign Therapeutics, Inc.
$9.84$591M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. DSGN
  4. Financial Ratios

Design Therapeutics, Inc. (DSGN) Financial Ratios

Latest Ratios: P/E Ratio -8.1x · EV/EBITDA N/A · ROE -30.7%. (2019–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

DSGN Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Market Cap$591M$538M$349M$148M$572M$984M——
Enterprise Value$576M$522M$329M$130M$549M$689M——
P/E Ratio →-8.06———————
P/S Ratio————————
P/B Ratio2.552.531.440.531.752.57——
P/FCF————————
P/OCF————————

P/E links to full P/E history page with 30-year chart

DSGN EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
EV / Revenue————————
EV / EBITDA————————
EV / EBIT————————
EV / FCF————————

DSGN Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Gross Margin———————-98.3%
Operating Margin———————-228777.0%
Net Profit Margin———————-245443.6%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
ROE-30.7%-30.7%-19.1%-22.1%-17.8%-19.2%——
ROA-29.2%-29.2%-18.3%-21.2%-17.3%-16.6%-45.2%-2274.4%
ROIC-28.4%-28.4%-19.4%-20.8%-25.9%-73.1%——
ROCE-34.8%-34.8%-23.8%-25.6%-18.9%-17.1%-56.0%—

DSGN Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Debt / Equity0.010.010.010.010.010.01——
Debt / EBITDA————————
Net Debt / Equity—-0.07-0.08-0.07-0.07-0.77——
Net Debt / EBITDA————————
Debt / FCF————————
Interest Coverage————————

Net cash position: cash ($17M) exceeds total debt ($2M)

DSGN Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Current Ratio17.1417.1429.3129.5831.1072.9615.550.02
Quick Ratio17.1417.1429.3129.5831.1072.9615.550.02
Cash Ratio16.8416.8429.0129.2930.6672.7015.490.02
Asset Turnover———————0.01
Inventory Turnover————————
Days Sales Outstanding————————

DSGN Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Dividend Yield————————
Payout Ratio————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Earnings Yield————————
FCF Yield————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%——
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%——
Shares Outstanding—$57M$57M$56M$56M$46M$27M$27M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Limited cash runway against burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Negative Earnings Leave Multiples Uninformative

With trailing P/E at -9.16 and P/B at 2.91 per reported figures, DSGN's earnings-based multiples are not meaningful, leaving book value and the equity base as the only usable reference points for an unprofitable pre-revenue company.

The negative P/E reflects a loss-making profile rather than a valuation signal, so comparison against own history or peers should rely on P/B and cash-based measures instead. The P/B of 2.91 sits above the peer FULC at 0.68, which suggests the market is paying a premium over reported book equity, likely reflecting the value placed on the GeneTAC platform and pipeline optionality rather than current earnings. Investors should monitor whether this premium narrows as cash declines and the balance sheet shrinks.

Returns Deteriorating as Losses Widen

Per reported ratios, ROE moved from -4.4% in 2024Q2 to -10.0% in 2026Q3 and ROIC from -4.9% to -8.8%, indicating that capital is being consumed at a faster pace as operating losses scale with R&D spend.

The decline in ROE and ROIC reflects growing losses against a shrinking equity base, which is the mechanical outcome of a development-stage company funding clinical programs from its balance sheet. Because the company has no revenue, these returns are driven entirely by the expense base, and ROIC trends here tell us about burn relative to capital rather than about operating efficiency. The trajectory suggests capital is decaying rather than compounding, and this warrants monitoring alongside any future financing that could reset the equity base.

Current Ratio Masks Thin Cash Coverage

Reported current ratio of 16.78 in 2026Q3, down from 41.42 in 2024Q2, looks robust on the surface, but based on reported figures cash of $15.3M covers only about one quarter of free cash flow burn near -$15.4M.

The high current ratio is a function of a small liability base relative to current assets, but the ratio itself does not reveal how quickly those assets are consumed by operations. The steady decline from 41.42 to 16.78 across ten quarters indicates current assets are being drawn down faster than current liabilities are growing. Under a stress scenario where financing is delayed, the position appears to offer limited headroom, and investors should monitor the next financing event closely.

Minimal Debt Reflects Equity-Funded Model

Debt-to-equity of 0.01 across all reported quarters, with interest coverage not reported, indicates that DSGN's development is funded almost entirely through equity, shifting the risk from creditor covenants to dilution.

Leverage is not the binding constraint here because the company carries negligible debt relative to its equity base, so covenant and refinancing risk appears low on reported figures. The relevant risk is instead the dilution that equity funding implies for existing shareholders as cash is consumed. Interest coverage is unavailable given the absence of meaningful interest expense, so the analysis rests on the debt ratio alone.

Misapplied Current Ratio Obscures Runway

The current ratio is the metric most commonly misapplied to this pre-revenue model, because it treats the company as a going concern with stable operations when reported burn suggests a much shorter effective runway.

The current ratio ignores the rate of cash consumption and implicitly assumes current assets will be available to meet obligations over a normal operating cycle, which does not fit a company with no revenue and quarterly free cash flow of roughly -$15.4M. A more useful alternative is months of runway, calculated as cash divided by quarterly burn, which on reported figures points to about one quarter of coverage. Investors should weight runway and financing timing above the headline current ratio when assessing this business.

Download Financial Ratios Data

Includes 30+ ratios · 7 years · Updated daily

Consensus & Technical Research Suite
Open DSGN Terminal

DSGN Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

DSGN — Frequently Asked Questions

Quick answers to the most common questions about buying DSGN stock.

What is Design Therapeutics, Inc.'s P/E ratio?

Design Therapeutics, Inc.'s current P/E ratio is -8.1x. This places it at the 50th percentile of its historical range.

What is Design Therapeutics, Inc.'s ROE?

Design Therapeutics, Inc.'s return on equity (ROE) is -30.7%. The historical average is -21.8%.

Is DSGN stock overvalued?

Based on historical data, Design Therapeutics, Inc. is trading at a P/E of -8.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.